

DIABETIC RETINOPATHY AND ITS SYSTEMIC RISK FACTORS**Anjum A.¹, Ahmed S.², Waris A.*³ and Akhtar N.⁴**^{1,4}Ms Ophthalmology, Institute of Ophthalmology, Jnmch, Amu, Aligarh.²Faculty of Medicine, Al Imam Mohammad Ibn Saud Islamic University, Riyadh, Kingdom of Saudi Arabia.³Ms, Fico (Uk), Fics (Usa), Frcs (Glasg), Frcs (Edin), Vr Faculty, Institute of Ophthalmology, Jnmch, Amu, Aligarh).Article Received on
09 September 2017,Revised on 30 Sept. 2017,
Accepted on 20 October 2017

DOI: 10.20959/wjpr201714-9954

Corresponding Author*Waris A.**Ms, Fico (Uk), Fics (Usa),
Frcs (Glasg), Frcs (Edin),
Vr Faculty, Institute Of
Ophthalmology, Jnmch,
Amu, Aligarh).**ABSTRACT**

Diabetes mellitus (DM), commonly referred to as diabetes, is a group of metabolic disorders with complications that include sight-threatening diabetic retinopathy, also known as diabetic eye disease. To implement an effective prevention the risk factors of diabetic retinopathy are essential to understand. This research aims to examine the association between the commonest complications of diabetes namely Diabetic retinopathy and its risk factors. Studies show there is a poor glycemic control in patients of diabetic retinopathy as reflected by a raised glycated hemoglobin, longer standing diabetes, and use of injectable insulin for treatment. Among other risk factors, hypertension has association with prevalence and progression of diabetic retinopathy

whereas the effects are not so well established for cholesterol, and lipid control, inflammatory markers, sleep-disordered breathing, obesity and exercise. Myopia was a protective factor for the development of diabetic retinopathy. Several genetic polymorphisms are also associated with an increased risk for development of diabetic retinopathy.

KEYWORDS: Diabetic retinopathy, Hypertension, Cholesterol, Exercise, Obesity, Sleep-disordered breathing, Anemia, Sex Hormones.

INTRODUCTION

Diabetes mellitus (diabetes) includes a group of metabolic disorders in which raised and dysregulated blood glucose levels result from either decreased production of insulin or insulin resistance.^[2] Diabetes in India is fast gaining the status of an epidemic with around more than

62 million diabetic individuals currently diagnosed with the disease. The prevalence of diabetes is predicted to double globally from 171 million in 2000 to 366 million in 2030 with a maximum increase in India]. Diabetes mellitus may afflict upto 79.4 million individuals in India by 2030, while China and the United States will also see significant rise in those suffering from the disease. Even with increasing number of treatment modalities for diabetic retinopathy, the best method of minimizing its impact is prevention of ocular complications. Insulin resistance, being at the heart of pathology of diabetes mellitus is not the only problem but is one of the components of this metabolic syndrome. Other features of the metabolic syndrome including dyslipidemia, hypertension, abdominal obesity, prothrombotic and a proinflammatory state are more likely to be found in a diabetic subject.^[4] If one or more of these components are present in the patient suffering from diabetes there is an increased risk of diabetic complications, including retinopathy.^[5] At the forefront of managing the disease are primary care physicians, endocrinologists and ophthalmologists who help to motivate patients to control their disease. The time of diagnosis of diabetic eye disease can be a pivotal moment in the patients' lives. Subjects with threat of vision loss is a wake-up call for them to invest in habits that will maintain their overall health and the health of their eyes. Various risk factors that affect one of the most important complications of Diabetes ie. diabetic eye disease has been studied in this research.

MATERIAL AND METHOD

This research was carried out by searching various classical text books along with medical database like PubMed, Google scholar. The authors each independently carried out a narrative literature review and findings were discussed. Literature was identified via searches of PubMed, Google and Google Scholar, with relevant publications selected after discussion. An important consideration was that papers either had risk factors for diabetic retinopathy or contained a detailed description of diabetic retinopathy. For PubMed and Google searches, similar terms were used. For example, the PubMed strategy consisted of title and abstract searches for: ((diabetic retinopathy) OR ((diabetic retinopathy AND risk factors))). Also searched upon were the recommendations of conferences and seminars, and reference lists from key publications.

RESULTS AND DISCUSSION

Glycemic control

The effects of raised blood sugar have been found to show the most significant effect on the progression of diabetes and the development of its complications particularly microvascular complications.^[6] In Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, patients were randomized to an intensive blood sugar control regimen with a target HbA1c level of 6.0 % were found to have a significantly lower rate of progression of diabetic retinopathy as compared to those with a HbA1c target level of 7.0–7.9 % (7.3 vs 10.4 % progression rate).^[7] Similar levels were found in subjects on a regimen of intensive control of glucose in type 2 diabetics in Cochrane review.^[8] For every 10 % decrease in HbA1c, there is an associated 42 % decreased risk of retinopathy progression. Whereas for every 10 % increase in HbA1c, the risk of retinopathy progression increased by 64 %.^[9] This study results are similar to previous studies, which also found a reduction in the risk of retinopathy with strict glycemic control.^[10,11] The beneficial effects of tight glycemic control seems to last for a longer time, as similarly managed patients in the Epidemiology of Diabetes Interventions and Complications Trial (EDIC) extension to the Diabetes Control and Complications Trial (DCCT) had a significantly lower risk of retinopathy progression if they were previously randomized to strict insulin therapy vs. conventional therapy (39 vs 56 % progression over 3 years).^[12] A new therapeutic modality for diabetes has emerged in form of pancreas transplantation. This has dramatic effects on blood sugars, with a number of patients achieving a euglycemic state. Cases have been reported on decreased progression or even regression of diabetic retinopathy after transplantation of pancreas.^[13,14] A class of medications used for control of blood sugar namely thiazolidinedione are considered to be controversial because of their ocular adverse effects including diabetic macular edema and resistant peripheral edema as its systemic side effect.^[15,16] However the ACCORD trial, compared the rates of macular edema with or without exposure to these drugs and saw no effect.^[17] Conclusively, strict control of blood sugar levels is definitely helpful in decreasing the progression of complications of Diabetes, particularly Diabetic retinopathy. The ideal levels of HbA1c target for diabetics still remains controversial. The American Diabetes Association advocates for a goal 7.0 % where as in ACCORD trial a HbA1c goal of 6.0 % was used and similarly a goal of 6.5 % was used by the ADVANCE trial.^[7]

Arterial Hypertension

BP control is an important component of risk factor modification in lowering the risk of progression of diabetes to develop retinopathy. Hypertension is very often coexistent with diabetes. Hypertension is three times more common in patients with diabetics as compared to non-diabetics. With respect to the risk for developing cardiovascular disease, diabetics are particularly susceptible to effects of hypertension. There are multiple hypotheses for why this may be. A review article showed that diabetics and hypertension coexist in people with type 2 diabetes mellitus in a range from 20.6% in India to 78.4% in Thailand in south East Asia. One of the implicated mechanism is the interactions between blood sugar control by hormones and the renin-angiotensin- aldosterone system (RAS) at many levels and in both directions; those with diabetes have elevated RAS leading to hypertension, and those with hypertension have higher rates of developing diabetes. The reduced risk of developing diabetes in hypertensive subjects and also reduced in risk of developing hypertension in previously normotensive diabetics has been seen with pharmacologic blockade of the RAS.^[19] An increased mortality rate, largely due to cardiovascular disease has been associated with combination of hypertension and diabetes in subjects. Diabetics with optimal blood pressure control have only 70 % risk of mortality as compared to poorly controlled hypertensive subjects, who have almost double the risk of death from cardiovascular disease.^[21] Naturally enough coexisting hypertension and diabetes have a higher incidence of developing retinopathy. Studies on diabetics with hypertension have shown that the relative risk of developing diabetic retinopathy is 1.7.^[21,23] One study shows that the risk of diabetic retinopathy increased by 1.23 times and by 1.19 times for a vision-threatening retinopathy for every increase in systolic blood pressure by 10 mmHg.^[24] A reduced risk with increasing diastolic blood pressure was identified in the same study that shows a 0.71 relative risk of diabetic retinopathy and 0.65 relative risk of vision-threatening retinopathy for every 10 mmHg increase in diastolic blood pressure.^[24] The rate of progression of diabetic retinopathy showed to reduce by 34 % over 7.5 years with treatment of hypertension (goal blood pressure less than 150/85).^[22,25] Also, efforts of reducing the blood pressure in hypertensive diabetics reduced the risk of vision loss of three lines or more by 47 %. There are beneficial effects of treatment of increased blood pressure to prevent diabetic retinopathy but not for slowing its progression as found in a Cochrane review.^[26] Subjects on intensive blood pressure control (goal systolic blood pressure 120 mmHg) and those on standard management (goal 140 mmHg) showed no significant difference in rate of progression diabetic retinopathy in the

ACCORD trial. As per the regulations of Joint National Committee 8, the control of blood pressure to a level of 140/90 mm of Hg is recommended.^[27]

High Cholesterol and Hyperlipidemia

Elevated levels of serum cholesterol and lipid are pillars of the metabolic syndrome. Studies show that an increased serum cholesterol and lipid levels have been linked to an elevated risk of vision loss in diabetic retinopathy. The average baseline cholesterol level of 244 was found in subjects with a persistent drop in vision to 5/200 or worse, as compared to a level of 228 in those who did not develop such loss in one of the study.^[28] Diabetics with macular edema have increased levels of total cholesterol, low-density lipoproteins, and serum triglycerides as shown in a meta-analysis.^[29] Elevated levels of lipids and cholesterol are associated with increased rates of hard retinal exudates. Study showed that the subjects with cholesterol level 240 mg/dL were twice as likely to have hard retinal exudates as compared to those with a cholesterol level 200 mg/dL. Also those with low-density lipoprotein cholesterol of 160 mg/dL as compared to those with 130 mg/dL, have double chances to have hard retinal exudates. Subjects with very-low density lipoprotein cholesterol level of 61 mg/dL— have a 1.84 times risk of having hard retinal exudates as compared to those with 18 mg/dL.^[28] Statistically a non-significant effects of high-density lipoprotein cholesterol and triglycerides was seen in the in this study. Effect of cholesterol and lipids on risk to develop diabetic eye disease has not been found in other studies.^[24,30] A commonly used treatment for elevated cholesterol is statins (HMG-CoA reductase inhibitors) whose use prior to diagnosis of diabetes is significantly associated with a reduced rate of development of diabetic retinopathy^[31] and its use in those with existing retinopathy has been associated to improved average visual acuity^[32] A class of medications for the treatment of hyperlipidemia is fibrates. In the ACCORD trial, there were 10,251 participants with type 2 diabetes enrolled in this randomized trial. In the lipid arm of ACCORD study, 5518 patients with dyslipidemia were assigned randomly to receive simvastatin in combination with either fenofibrate or matching placebo. At 4 years, the rates of progression of diabetic retinopathy were 7.3% with intensive glycaemia treatment (HbA1c < 6.0%) versus 10.4% with standard therapy (HbA1c level, 7.0 to 7.9%, p=0.003); 6.5% with fenofibrate for intensive dyslipidemia therapy, versus 10.2% with placebo (p=0.006); and 10.4% with intensive blood pressure therapy, versus 8.8% with standard therapy (p=0.29).^[7] The study found a reduction in chance for laser treatment for diabetic retinopathy for those who received fenofibrate as compared to those only on a placebo.^[33] An additional retinal benefits may be offered by fibrates for a diabetic patients

but further study is required for this medication to be ideal for managing of retinopathy in diabetes.

Obesity

Association between obesity and diabetes exists. There is a five times higher chance of developing diabetes in individual with class 3 obesity (body mass index of 40) as compared to one with a normal weight.^[35] There is an increased chance of developing diabetic retinopathy in those having high body mass index.^[36] An increased body mass index and obesity may have a protective effect as shown by few studies [37–39]. An increased rate of diabetic retinopathy has been found in those with a higher waist-to-hip ratio, which is a reliable marker for abdominal obesity.^[40,41] Both, the severity and the risk of diabetic retinopathy has been found to be higher in presence of increased neck and waist circumference.^[41] The major component of metabolic syndrome is obesity and the subjects should be motivated to lose weight and keep a check. Bariatric surgery and its effects on diabetic retinopathy is not well defined and appears to be unpredictable.^[42,43]

Inflammatory markers

Various markers of inflammation are associated with increased risk of neoplasia and cardiovascular disease. An association with diabetic retinopathy is also found. An elevated level of CRP was shown in patients of diabetic retinopathy as compared to those without diabetic retinopathy.^[36,44] The risk of retinal hard exudates and clinically significant macular edema are high and are associated with increased CRP levels.^[39,44]

Sleep-disordered breathing

Obstructive sleep apnea (OSA) or Sleep-disordered breathing causes frequent upper airway obstructions leading to blood oxygen desaturation and sleep disruption. It can lead to morbidity and is frequently associated with obesity. In one of the studies, after an overnight oximetry monitoring, it was found that 86 % of obese diabetic patients met the criteria for diagnosis of obstructive sleep apnea^[45] Frequent and repeated hypoxia is associated with OSA can lead to oxidative stress at the endothelial level which can later progress to vascular dysfunction and angiogenesis.^[46] An increased rate of diabetic retinopathy has been seen in subjects with Obstructive sleep apnea (OSA).^[47,48] Obstructive sleep apnea (OSA) and macular edema may be linked as shown in study;^[50] and a poor response has been shown with use of anti-vascular endothelial growth factor agents.^[51]

Exercise

Studies show that there is a 75 % decreased risk of developing diabetic retinopathy with a daily 10 minutes exercise of moderate to vigorous category and a 94% reduction in risk in women with a daily 20 minutes exercise.^[52] There is no statistical significance difference for men. Low intensity leisure time physical activity. Low-frequency leisure time physical activity shows 1.49 times higher risk for diabetic retinopathy and can lead to a 2.58 elevated rate of diabetic retinopathy.^[53] 60 minutes of physical activity daily is the current recommendation for adults and it should comprise of at least 15 min of work related activity, 15 min of muscle strengthening exercises and 30 minutes of moderate intensity aerobic activity.

Anemia

Anemia is more common in patients with diabetes than in persons without diabetes. There is an early onset of anemia and is of more severity in patients with diabetes as compared with patients having renal functions impaired due to causes other than diabetes. According to the recommendations of the World Health Organization (WHO), one should investigate for anemia in women if Hb level is less than 12 g/dL and in men if it is less than 13g/dL in men. As per these guidelines nearly 1 out of 4 patients suffering from type 1 or type 2 diabetes were found out to have associated anemia. There is found to be an association of anemia with the increased incidence and progression of both microvascular and macrovascular complications of diabetes. The reason for the aforementioned problem can be because of falsely low levels of HbA1c in patients having anemia and eventual under treatment of hyperglycemia and hence more rapid development and progression of the complications of diabetes including retinopathy. According to Quing Quio et al, there is a reported odds of 5 for severe retinopathy with presence of anemia. Similar risk between the two was also reported by Shorb in a case series.

Sex Hormones

Gupta et al^[62] showed that there is dissimilarity in ocular pathophysiology between females and males of humans. Such differences are seen in the lacrimal and associated glands, crystalline lens, ocular surface, and retinoblastoma. These differences are mainly due to sex steroid hormones and physiological conditions, such as age, menstrual cycles, pregnancy, and menopause or andropause, where there is alteration of the hormone milieu that affects the vision.

There is ample evidence that sex hormones do play a role in development and progression of diabetic retinopathy in humans and a study by Anjum A et al^[63] also showed that sex hormones do play a role at several different stages of retinopathy and that sex hormone stimulation or modulation, can offer promise to control diabetic retinopathy. Wisconsin Epidemiological Study of Diabetic Retinopathy (WESDR) were done with predominantly white cohorts (Klein et al;^[64] Klein et al^[65] and the 25 year results of this WESDR showed that being a male was an independent risk factor for progression of diabetic retinopathy. A study by Haffner et al,^[66] suggested that changes in sex hormones may influence the development of diabetic retinopathy. They measured serum testosterone, estradiol, DHEA-S and sex hormone binding globulin levels in subjects with type I diabetes from the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), and found that the serum testosterone concentrations were significantly higher in male diabetic subjects with proliferative retinopathy than in male diabetic subjects with minimal or no retinopathy. A study in India by Raman et al^[67] also demonstrated increased risk of diabetic retinopathy for men who develop diabetes over the age of forty.

Diabetic retinopathy presents a major problem during child bearing years and deleterious effects of diabetic retinopathy during pregnancy have been documented. A study by Vargas et al^[70] showed that 10% of all pregnancies have complications as a result of diabetes mellitus in United States. The occurrence and progression of retinopathy were related to the mean blood glucose levels and the serum concentrations of prolactin, human placental lactogen, estradiol and progesterone in pregnant insulin-dependent diabetic patients was shown by Larinkari J et al.^[68] Throughout gestation, serum prolactin concentrations were significantly lower in diabetic patients than in healthy subjects. Further, the influence of hormonal alterations during pregnancy on the worsening of diabetic retinopathy was studied by Sone et al.^[69] They examined the effects of estradiol (E2) and progesterone (P4) on the production of vascular endothelial growth factor (VEGF) in bovine retinal pigment epithelial cells in culture. As the increase in serum P4 levels during pregnancy is reported to be greater in pregnant diabetic patients with progressive retinopathy, their findings suggested that P4 may contribute to the worsening of diabetic retinopathy during pregnancy by up-regulating intraocular vascular endothelial growth factor (VEGF) levels. An in depth understanding of role of sex hormones in development and progression of diabetic retinopathy is of importance.

CONCLUSIONS

Diabetic retinopathy is the most common complication of diabetes mellitus that impairs the individual functioning and diminishes the quality of life. It ultimately imposes severe health burden on society and can cause significant morbidity if not addressed appropriately. The modifiable and non-modifiable risk factors are found to be the reason for the development of the diabetic retinopathy. The treatment modalities for management of diabetic retinopathy are available and found to be efficacious in different controlled studies, but the best treatment is prevention and strict control of the risk factors. In conclusion, overall health of the patients affects the development of diabetes and diabetic retinopathy. Health education about the maintenance of good systemic health and motivation of patients to strive for better management of issues related to health is a shared responsibility of ophthalmologists and other eye care providers.

REFERENCES

1. Economic costs of diabetes in the U.S. in 2012. *Diabetes Care*, 2013; 36(4): 1033–46.
2. Boyle JP, Thompson TJ, Gregg EW, et al. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. *Popul Health Metr*, 2010; 8: 29.
3. Saaddine JB, Honeycutt AA, Narayan KM, et al. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States, 2005–2050. *Arch Ophthalmol*, 2008; 126(12): 1740–7.
4. Third Report of the National Cholesterol Education Program. (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. *Circulation*, 2002; 106(25): 3143–421.
5. Costa LA, Canani LH, Lisboa HR, et al. Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in Type 2 diabetes. *Diabet Med*, 2004; 21(3): 252–5.
6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med*, 1993; 329(14): 977–86.
7. Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. *N Engl J Med*, 2010; 363(3): 233–44.

8. Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. *Cochrane Database Syst Rev*, 2013; 11: 008143.
9. Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. *Diabetes*, 1995; 44(8): 968–83.
10. Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. *Ophthalmology*, 1995; 102(4): 647–61.
11. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. *N Engl J Med*, 1993; 329(5): 304–9.
12. Lachin JM, White NH, Hainsworth DP, et al. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/ EDIC. *Diabetes*, 2015; 64(2): 631–42. This is a continuation of the landmark Diabetes Control and Complications Trial, which established the lower rate of microvascular complications for intensive glucose control in type 1 diabetes. Previous follow up studies showed the effect of “metabolic memory” where the effects of the intensive glucose management persisted through 10 years of follow up. This extension showed that 18 years after the trial both groups have the same yearly incidence of diabetic microvascular complications, likely due to better glycemic control in the former conventional treatment group.
13. Pearce IA, Ilango B, Sells RA, Wong D. Stabilisation of diabetic retinopathy following simultaneous pancreas and kidney transplant. *Br J Ophthalmol*, 2000; 84(7): 736–40.
14. Shipman KE, Patel CK. The effect of combined renal and pancreatic transplantation on diabetic retinopathy. *Clin Ophthalmol*, 2009; 3: 531–5.
15. Colucciello M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. *Arch Ophthalmol*, 2005; 123(9): 1273–5.
16. Ryan EH Jr, Han DP, Ramsay RC, et al. Diabetic macular edema associated with glitazone use. *Retina*, 2006; 26(5): 562–70.
17. Ambrosius WT, Danis RP, Goff DC Jr, et al. Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. *Arch Ophthalmol*, 2010; 128(3): 312–8.

18. Navar-Boggan AM, Pencina MJ, Williams K, et al. Proportion of US adults potentially affected by the 2014 hypertension guideline. *JAMA*, 2014; 311(14): 1424–9.
19. Zhou MS, Schulman IH. Prevention of diabetes in hypertensive patients: results and implications from the VALUE trial. *Vasc Health Risk Manag*, 2009; 5(1): 361–8.
20. Wang B, Wang F, Zhang Y, et al. Effects of RAS inhibitors on diabetic retinopathy: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol*, 2015; 3(4): 263–74.
21. Walraven I, Mast MR, Hoekstra T, et al. Real-world evidence of suboptimal blood pressure control in patients with type 2 diabetes. *J Hypertens*, 2015; 33: 2091–8.
22. Raum P, Lamparter J, Ponto KA, et al. Prevalence and cardiovascular associations of diabetic retinopathy and maculopathy: Results from the Gutenberg Health Study. *PLoS One*, 2015; 10(6): 0127188.
23. Wong TY, Cheung N, Tay WT, et al. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. *Ophthalmology*, 2008; 115(11): 1869–75.
24. Zheng Y, Lamoureux EL, Lavanya R, et al. Prevalence and risk factors of diabetic retinopathy in migrant Indians in an urbanized society in Asia: the Singapore Indian eye study. *Ophthalmology*, 2012; 119(10): 2119–24.
25. Jin P, Peng J, Zou H, et al. A five-year prospective study of diabetic retinopathy progression in chinese type 2 diabetes patients with “well-controlled” blood glucose. *PLoS ONE*, 2015; 10(4): 0123449.
26. Doe DV, Wang X, Vedula SS, et al. Blood pressure control for diabetic retinopathy. *Cochrane Database Syst Rev*, 2015; 1: CD006127.
27. Armstrong C. JNC8 guidelines for the management of hypertension in adults. *Am Fam Physician*, 2014; 90(7): 503–4.
28. Chew EY, Klein ML, and Ferris FL 3rd, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. *Arch Ophthalmol*, 1996; 114(9): 1079–84.
29. Das R, Kerr R, Chakravarthy U, Hogg RE. Dyslipidemia and diabetic macular edema: a systematic review and meta-analysis. *Ophthalmology*, 2015; 122: 1820–7. This meta-analysis examined prospective randomized control trials to determine if there was an effect of dyslipidemia on diabetic macular edema, as suggested by some earlier cohort and case-control studies. They did not find such a link.
30. Klein R, Sharrett AR, Klein BE, et al. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities study. *Ophthalmology*, 2002; 109(7): 1225–34.

31. Nielsen SF, Nordestgaard BG. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study. *Lancet Diabetes Endocrinol*, 2014; 2(11): 894–900.
32. Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. *Diabetes Res Clin Pract*, 2002; 56(1): 1–11.
33. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. *Lancet*, 2007; 370(9600): 1687–97.
34. Talbert RL. Role of the National Cholesterol Education Program Adult treatment panel III guidelines in managing dyslipidemia. *Am J Health Syst Pharm*, 2003; 60(13 Suppl 2): S3–8; quiz S25.
35. Nguyen NT, Magno CP, Lane KT, et al. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. *J Am Coll Surg*, 2008; 207(6): 928–34.
36. Cekic S, Cvetkovic T, Jovanovic I, et al. C-reactive protein and chitinase 3-like protein 1 as biomarkers of spatial redistribution of retinal blood vessels on digital retinal photography in patients with diabetic retinopathy. *Bosn J Basic Med Sci*. 2014; 14(3): 177–84.
37. Klein R, Klein BE, Moss SE. Is obesity related to microvascular and macrovascular complications in diabetes? The Wisconsin Epidemiologic Study of Diabetic Retinopathy. *Arch Intern Med*, 1997; 157(6): 650–6.
38. Raman R, Rani PK, Gnanamoorthy P, et al. Association of obesity with diabetic retinopathy: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study (SNDREAMS Report no. 8). *Acta Diabetol*, 2010; 47(3): 209–15.
39. Lim LS, Tai ES, Mitchell P, et al. C-reactive protein, body mass index, and diabetic retinopathy. *Invest Ophthalmol Vis Sci*, 2010; 51(9): 4458–63.
40. Porta M, Sjoelie AK, Chaturvedi N, et al. Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. *Diabetologia*, 2001; 44(12): 2203–9.
41. Dirani M, Xie J, Fenwick E, et al. Are obesity and anthropometry risk factors for diabetic retinopathy? The diabetes management project. *Invest Ophthalmol Vis Sci*, 2011; 52(7): 4416–21.

42. Thomas RL, Prior SL, Barry JD, et al. Does bariatric surgery adversely impact on diabetic retinopathy in persons with morbid obesity and type 2 diabetes? A pilot study. *J Diabetes Complications*, 2014; 28(2): 191–5.
43. Varadhan L, Humphreys T, Walker AB, et al. Bariatric surgery and diabetic retinopathy: a pilot analysis. *Obes Surg*, 2012; 22(3): 515–6.
44. Muni RH, Kohly RP, Lee EQ, et al. Prospective study of inflammatory biomarkers and risk of diabetic retinopathy in the diabetes control and complications trial. *JAMA Ophthalmol*, 2013; 131(4): 514–21.
45. Foster GD, Sanders MH, Millman R, et al. Obstructive sleep apnea among obese patients with type 2 diabetes. *Diabetes Care*, 2009; 32(6): 1017–9.
46. Dewan NA, Nieto FJ, Somers VK. Intermittent hypoxemia and OSA: implications for comorbidities. *Chest*, 2015; 147(1): 266–74.
47. Shiba T, Sato Y, Takahashi M. Relationship between diabetic retinopathy and sleep-disordered breathing. *Am J Ophthalmol*, 2009; 147(6): 1017–21.
48. Rudrappa S, Warren G, Idris I. Obstructive sleep apnoea is associated with the development and progression of diabetic retinopathy, independent of conventional risk factors and novel biomarkers for diabetic retinopathy. *Br J Ophthalmol*, 2012; 96(12): 1535.
49. Shiba T, Takahashi M, Hori Y, et al. Relationship between sleepdisordered breathing and iris and/or angle neovascularization in proliferative diabetic retinopathy cases. *Am J Ophthalmol*, 2011; 151(4): 604–9.
50. Mason RH, West SD, Kiire CA, et al. High prevalence of sleep disordered breathing in patients with diabetic macular edema. *Retina*, 2012; 32(9): 1791–8.
51. Nesmith BL, Ihnen M, Schaal S. Poor responders to bevacizumab pharmacotherapy in age-related macular degeneration and in diabetic macular edema demonstrate increased risk for obstructive sleep apnea. *Retina*, 2014; 34(12): 2423–30. This study found that those patients who responded poorly to anti-VEGF therapy had a higher risk of obstructive sleep apnea. This suggests that such patients should undergo screening for obstructive sleep apnea.
52. Loprinzi PD, Brodowicz GR, Sengupta S, et al. Accelerometerassessed physical activity and diabetic retinopathy in the United States. *JAMA Ophthalmol*, 2014; 132(8): 1017–9.
53. Waden J, Forsblom C, Thorn LM, et al. Physical activity and diabetes complications in patients with type 1 diabetes: the Finnish Diabetic Nephropathy (FinnDiane) Study. *Diabetes Care*, 2008; 31(2): 230–2.

54. Thomas MC, MacIsaac RJ, Tsalamandris C, Power D, Jerums G. Unrecognized anemia in patients with diabetes: a cross-sectional survey. *Diabetes Care*, 2003; 26(4): 1164-9.
55. Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. *Diabetes Care*, 2001; 24: 495-9.
56. World Health Organization. Nutritional anemias: Report of a WHO scientific group. WHO, Geneva, 1968.
57. Carmargo, J. L. Gross, J. L. Conditions associated with very low values of glycohaemoglobin measured by an HPLC method. *J Clin Pathol*, 2004; 57: 346-9.
58. Thankachan P, Muthayya S, Walczyk T, Kurpad AV, Hurrell RF. The burden of anemia among women in India. *Eur J Clin Nutr*, 2003; 57: 52-60.
59. Quio, Q, Keinanen-Kiukaanniemi, S, Laara E. The relationship between hemoglobin levels and diabetic retinopathy. *Journal of Clinical Epidemiology*, 1997; 50: 153-8.
60. Davis MD, Fisher MR, Gangnon RE, Barton F, Aiello LM, Chew EY, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. *Invest Ophthalmol Vis Sci*, 1998; 39: 233-52.
61. Shorb SR. Anemia and diabetic retinopathy. *Am J Ophthalmol*, 1985; 100(3): 434-6.
62. Gupta N, Gupta R. Diabetic Retinopathy- an Update. *Journal of International Medical Sciences Academy*, Jan – Mar 2015; 28(1): 54-58.
63. Anjum, A., Waris A, Akhtar N, Ahmed A, Ahmed S. Diabetic Retinopathy and Sex Hormones. *IOSR Journal of Dental and Medical Sciences*, 2017; 16(1 Ver VI): 110-115.
64. Klein, R., M. D. Knudtson, K. E. Lee, R. Gangnon and B. E. Klein "The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes." *Ophthalmology*, 2008; 115(11): 1859-1868.
65. Klein, R., K. E. Lee, R. E. Gangnon and B. E. Klein "The 25-year incidence of visual impairment in type 1 diabetes mellitus the wisconsin epidemiologic study of diabetic retinopathy." *Ophthalmology*, 2010; 117(1): 63-70.
66. Haffner, Steven M., Ronald Klein, James F. Dunn, Scot E. Moss, and Barbara EK Klein. "Increased testosterone in type I diabetic subjects with severe retinopathy." *Ophthalmology*, 1990; 97(10): 1270-1274.
67. Raman, R., K. Vaitheeswaran, K. Vinita and T. Sharma "Is prevalence of retinopathy related to the age of onset of diabetes? Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Report No. 5." *Ophthalmic research*, 2011; 45(1): 36-41.

68. Larinkari, J., L. Laatikainen, T. Ranta, P. Mörönen, K. Pesonen, and T. Laatikainen. "Metabolic control and serum hormone levels in relation to retinopathy in diabetic pregnancy." *Diabetologia*, 1982; 22(5): 327-332.
69. Sone, Hirohito, Yukichi Okuda, Yasushi Kawakami, Shinichi Kondo, Mitsuya Hanatani, Katsuhiko Matsuo, Hideo Suzuki, and Kamejiro Yamashita. "Progesterone induces vascular endothelial growth factor on retinal pigment epithelial cells in culture." *Life sciences*, 1996; 59(1): 21-25.
70. Vargas, R., J. T. Repke and S. H. Ural "Type 1 diabetes mellitus and pregnancy." *Reviews in obstetrics and gynecology*, 2010; 3(3): 92-100.